Ellen Dexter, RPH (PHARMACIST) Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 39 Flint Locke Ln, Medfield, MA 02052 Phone: 781-762-1561 |
Mr. Mojtaba Ghavidel Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 230 Main St, Medfield, MA 02052 Phone: 508-359-6855 Fax: 508-359-7519 |
Lindsay Backlund Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 555 Main St, Medfield, MA 02052 Phone: 508-359-7783 |
Mr. Stephen Christopher Dragotakes, RPH. , BCNP Pharmacist - Nuclear Medicare: Not Enrolled in Medicare Practice Location: 18 Hillcrest Rd, Medfield, MA 02052 Phone: 508-359-7214 |
Dr. Phuoc Vo Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 555 Main St, Medfield, MA 02052 Phone: 508-359-7783 Fax: 508-359-7381 |
Phuong Pham Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 555 Main St, Medfield, MA 02052 Phone: 508-359-7783 |
News Archive
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for claims in U.S. patent application no. 11/781,165.
Parkinson's disease is a neurodegenerative disorder that affects dopamine-producing or dopaminergic neurons. The progressive loss of these neurons is what leads to impairment in movement coordination in those suffering from the illness.
The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that the company will continue to follow its current insurance coverage guidelines for mammography screenings.
The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.
BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
› Verified 8 days ago